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Advances in experimental capabilities in the glycosciences offer expanding opportunities
for discovery in the broad areas of immunology and microbiology. These two disciplines
overlap when microbial infection stimulates host immune responses and glycan structures
are central in the processes that occur during all such encounters. Microbial glycans mediate
host-pathogen interactions by acting as surface receptors or ligands, functioning as virulence
factors, impeding host immune responses, or playing other roles in the struggle between
host and microbe. In the context of the host, glycosylation drives cell–cell interactions that
initiate and regulate the host response and modulates the effects of antibodies and soluble
immune mediators. This perspective reports on a workshop organized jointly by the National
Institute of Allergy and Infectious Diseases and the National Institute of Dental and Craniofacial
Research in May 2020. The conference addressed the use of emerging glycoscience tools
and resources to advance investigation of glycans and their roles in microbe-host interactions,
immune-mediated diseases, and immune cell recognition and function. Future discoveries
in these areas will increase fundamental scientific understanding and have the potential to
improve diagnosis and treatment of infections and immune dysregulation.
Keywords: glycobiology, glycomedicine, glycoscience, host response, infection, immunity, microbial glycans

INTRODUCTION
During the early months of the COVID-19 pandemic (May 27–28, 2020), an NIH workshop
on “Glycoscience and Immunology at the Crossroads of Biology” was convened on-line. The
component topics of the workshop were infection, immunity, and glycobiology. Each of these
broad areas is the subject of intense scientific investigation, and resulting discoveries have
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advanced human health. Many studies also occur at the
intersections of these fields. For example, infection and immunity
represent two views of the events that occur during and after
encounters between pathogenic microbes and their hosts.
Understanding how these events unfold from each vantage
point has been critical for the development of modern
immunology and microbiology and for the development of
strategies to treat immune dysregulation and infectious disease.
This perspective, like the NIH workshop on which it is based,
focuses on the overlap of glycoscience with each of these two
fields (Figure 1).
Glycans play key roles in infection and immunity: Pathogen
glycans may mediate host interactions and stimulate or inhibit
host immune responses, while host glycans may serve as specific
targets of microbial adhesion molecules or toxins (Varki and
Gagneux, 2015). Glycans also act in mediating the host response
to infection and in regulating immunity at multiple levels. In
all of these roles, their primary function is molecular recognition,
as opposed to their structural and dietary cousins (more often
termed sugars, saccharides, or carbohydrates).
This brief perspective will use the topics discussed at the
NIH workshop as examples to focus attention on emerging
areas of research and opportunities in the many areas of
infection and immunity where glycans play key roles. It will
also highlight the importance of glycoscience tools for scientific
progress on these topics and identify areas where investment
in basic research efforts will advance knowledge and practice
in glycobiology and glycomedicine.

FIGURE 1 | Glycoscience, infection, and immunity overlap in multiple areas
that drive pathogen and host function. Color-coded overlap topics mentioned
in the text are listed as examples.

roughly 200,000 deaths from meningitis each year, elaborates
an extracellular capsule that is composed of large (up to millions
of daltons) polysaccharides and can comprise >75% of the
pathogen volume. The capsule, made primarily of mannose
or galactose chains with appendant glucuronic acid and xylose
residues, is required for infection and inhibits host cell
phagocytosis (Gaylord et al., 2020). Shed capsule components
also perturb host immune responses; this material is also the
basis for rapid tests that are valuable for diagnosis of this
frequently lethal infection.
In addition to glycans produced by microbes themselves,
host glycoconjugates are critical in determining the outcomes
of host-pathogen interactions. Influenza virus is a compelling
example of this dual association of glycobiology and
pathogenesis. This virus exploits host glycans by using sialic
acid bearing proteins for cell entry (mediated by
hemagglutinin) and a sialidase (neuraminidase) to trigger
release of budding virions (Gamblin and Skehel, 2010); as
a result, species-specific differences in sialic acid isomers
impact the host selectivity of various strains. For example,
pathogenic human influenza strains all bear hemagglutinins
that bind sialic acid linked to the 6-carbon hydroxyl of
galactose whereas bird influenza binds to sialic acid when
linked to the 3-carbon hydroxyl of galactose. The molecular
switch in human to bird specificity can occur when as few
as two amino acids in the sialic acid binding site of influenza
hemagglutinin are appropriately mutated.
On the flip side, influenza also illustrates how microbial
protein glycosylation can impact host defenses. Seth Zost
discussed how antigenic drift in the influenza virus hemagglutinin
protein may alter its glycosylation, which in turn can change
characteristics of the infection, such as infectivity and viral
fitness, as well as the efficacy of host antibody responses that

GLYCANS IN HOST-PATHOGEN
RECOGNITION AND DISEASE
Microbial glycans are incredibly diverse and play critical roles
in the interactions between infectious agents and their hosts
and in the pathogenesis of resulting infections. These compounds
frequently constitute much of the microbial cell surface and
therefore mediate the initial encounters between pathogen and
host cells. Bacteria, for example, are protected by a peptidoglycan
cell wall and often display polysaccharide capsules as well as
other glycan-containing moieties. The cell walls of fungi are
primarily composed of glycan polymers and highly glycosylated
proteins. Many parasites display surface coats that are both
anchored by glycolipids and abundantly glycosylated. Study of
these glycans has revealed novel biological pathways, elucidated
pathogenic processes, and led to the development of vaccines
and therapeutics.
Microbial glycan structures contribute to pathogenesis by
an array of distinct mechanisms. They may physically protect
the invading pathogen, mediate cell adherence or protein
interactions, transmit signaling information, serve as decoys,
or alter the environment to the benefit of the invader, as when
biofilm production reduces the efficacy of antibiotics or efficiency
of host clearance. Tamara Doering presented the opportunistic
eukaryote Cryptococcus neoformans as an example of a pathogen
whose glycans are critical for the development of disease
(Loza and Doering, 2021). This yeast, which is responsible for
Frontiers in Microbiology | www.frontiersin.org
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neutralize the virus (Zost et al., 2017; Altman et al., 2019).
Vaccine efficacy may also change in this scenario, both because
the new antigen will induce a distinct antibody response and
because protection conferred by prior immunization may
be less robust.
The exploitation of host glycans by microbial invaders
to advance infection and disease occurs frequently across
domains of microbiology. For instance, Stefan Ruhl discussed
the contributions of host glycan recognition to the physiology
of the oral microbiome. The interactions between lectinlike adhesins on bacteria and complementary glycan motifs
on glycoproteins adsorbed to tooth enamel play central
roles in initial bacterial colonization. Lectin-glycan binding
also facilitates bacterial coadhesion that leads to the formation
of microbial biofilms. Glycan-driven bacterial-host
interactions are key both to establishing the commensal
oral microbiota and to oral disease progression (Thamadilok
et al., 2016; Cross and Ruhl, 2018). Host glycans can also
significantly impact pathogen behavior by modulating the
immediate pathogen environment. As a striking example,
Katharina Ribbeck presented the effects on epithelial microbes
of host mucus, which is often excluded from experiments
performed in vitro despite its known role in defense against
infection. Her group has shown that mucin-associated glycans
influence multiple microbial functions that are central to
pathogenic processes of yeast and bacteria, including surface
attachment, quorum sensing, virulence gene expression, and
biofilm formation. Released O-linked glycans from highly
glycosylated mucins, such as MUC5B, retain many of
these effects.

models. These findings make IgE glycosylation a promising
target for therapeutic modulation.
Human IgG Fc glycans also correlate with disease outcomes,
in both infectious and autoimmune diseases (Cobb, 2020). This
appears to be due to the ability of various IgG Fc glycoforms
to drive distinct Fc-dependent mechanisms and immune
outcomes, from activating immunity to supporting tolerance.
Intriguingly, glycoform expression may be specific for the
antigen eliciting the response. Evidently, B-cell glycan biosynthetic
enzymes respond to the antigen and regulate Fc glycosylation
to tune the downstream response (Larsen et al., 2021). For
both IgE and IgG, the technology has been developed to create
designer immunoglobulin glycans, thereby modulating immune
responses for therapeutic benefit.
Glycosylation of cell surface molecules on immune cells
also regulates immune outcomes. Michael Demetriou described
how the patterns of N-glycosylation on cell surface glycoproteins
control the distribution, clustering, and surface residency of
immune regulatory glycoproteins in a predictable manner. The
mechanism involves glycan-binding proteins called galectins
that, when N-glycans are sufficiently abundant and branched,
form a cell surface lattice of immune regulatory molecules on
both T cells and B cells (Mortales et al., 2020). Insufficient
branching of N-glycans can result in autoimmune sensitivity,
for example, in multiple sclerosis and autoimmune diabetes
(Brandt et al., 2021). Remarkably, oral administration of the
sugar N-acetylglucosamine in human subjects increases N-glycan
branching, raising the hope that dietary supplementation may
reduce autoimmunity.
Whereas GlcNAc-induced N-glycan branching regulates
cell surface residency on immune cells, the same single
sugar is dynamically attached to and removed from specific
serine and threonine residues of cytoplasmic, nuclear, and
mitochondrial proteins. This modification (O-GlcNAc)
modulates protein and cell functions in immunity, cancer,
neurodegeneration, and diabetes (among others) and is
regulated by a single transferase (OGT) and glycosidase
(OGA). Christina Woo shared new technologies to fuse
nanobodies to these enzymes to modulate the O-GlcNAc
residency of a particular protein or protein site (Ramirez
et al., 2020; Ge et al., 2021). These methods promise to
allow interrogation of the roles of O-GlcNAc on target
proteins and to decode O-GlcNAc regulation.
Once an immune response is elicited, it must be controlled
to avoid pathology due to the activated immune cells causing
host tissue damage. Glycans play a role in this process as
well. Ronald Schnaar described the 14-member family of human
glycan-binding proteins (GBPs) called Siglecs, most of which
are expressed on the surfaces of overlapping sets of immune
cells and most of which dampen immune responses via
intracellular immunoreceptor tyrosine-based inhibitory motifs
(Duan and Paulson, 2020). When inhibitory Siglecs on activated
immune cells encounter their native glycan ligands on target
tissues, the immune cells apoptose or are otherwise inhibited,
halting the ongoing immune event. Based on these findings,
Siglecs are being targeted therapeutically as immune checkpoint
inhibitors (Youngblood et al., 2020).

GLYCANS IN TUNING AND CONTROL
OF IMMUNE RESPONSES
As major molecular determinants on cell surfaces, on secreted
proteins, and in the extracellular matrix, glycans are well suited
to regulate molecular recognition and molecular signaling events.
Nowhere is this more evident than in the immune system,
where different types of immune cells respond to secreted
factors, each other, and molecules in their extracellular milieu
to coordinate pathogen clearance while avoiding damage to
host cells and tissues. Glycans and glycan recognition drive
and regulate immune responses at every level and provide
inviting and often untapped opportunities for therapeutic
development targeting immune dysregulation.
Among the most exciting recent findings is that humoral
immunity is tuned by antibody glycosylation. Robert Anthony
and Margaret Ackerman provided clinical and mechanistic
insights related to IgE and IgG glycosylation. Allergen-specific
IgE is absolutely required for allergic symptoms and disease.
Unbiased examination of glycosylation patterns of total IgE
from individuals with a peanut allergy and non-atopic
individuals revealed altered glycosylation – an increase in
sialic acid content – on IgE from allergic subjects (Shade
et al., 2020). Selective sialic acid removal from IgE lessened
effector-cell degranulation and anaphylaxis in allergic disease
Frontiers in Microbiology | www.frontiersin.org
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TOOLS AND RESOURCES FOR
GLYCOBIOLOGY

lectins, providing valuable reagents to further our understanding
of glycobiology (Angel et al., 2021; Büll et al., 2021).
Monoclonal antibodies are another powerful tool to examine
glycan localization and function. However, the mAbs available
to researchers bind only a small fraction of the predicted glycan
epitopes within the human glycome and fewer than a third
of them are reliably available from commercial sources (according
to a survey of the Database for Anti-Glycan Reagents); the
situation is even worse for mAbs that specifically recognize
microbial glycans. The paucity of such commercial reagents
forces many laboratories to produce their own mAbs, an
expensive solution that perpetuates problems of availability.
Finally, due to the similarity of the human and mouse glycomes,
human glycan structures are often not immunogenic and result
in the production of IgM mAbs with broader specificity. To
address these obstacles, Tanya McKitrick is developing “smart”
anti-glycan reagents (SAGRs) by immunizing the sea lamprey,
Petromyzon marinus, and then producing recombinant lamprey
antibodies with a mouse/rabbit Fc for detection purposes
(McKitrick et al., 2020, 2021). Lampreys have evolved an
alternative adaptive immune system that occurs only in jawless
vertebrates and uses a family of highly diverse, single-chain
antibody-like proteins called variable lymphocyte receptors B
(VLRBs). The potential diversity of SAGRs exceeds that of
antibody production in mice, studies to date have identified
over 25 VLRBs which can discriminate between glycosidic
linkages, functional groups, and monosaccharides. These VLRB
antibody sequences are publicly available in GenBank.
A further exciting area of tool development relates to proteinglycan interactions. Greg Hudalla discussed how galectins
recognize glycans of the cell surface and extracellular matrix
and thereby modulate biological processes, including those
relevant to inflammation and infection. His group has developed
peptide-based platforms to engineer multivalent scaffolds to
influence galectin interactions at the cellular level (Restuccia
et al., 2015; Farhadi et al., 2021). Beyond defining key biological
interactions, these approaches have potential application in
areas, including signaling, apoptosis, and drug delivery.

Despite significant advances in the study of glycosylation,
there is much to be learned regarding the biological roles
of these highly diverse molecules. For example, the human
glycome is predicted to be vast: Some estimates suggest well
over 7,500 unique structures, which require more than 700
genes for synthesis (Cummings, 2009). These structures are
further diversified with additional modifications, including
sulfation, methylation, and acetylation, which can directly
impact or alter the function of individual glycans. Progress
in the fields of glycomics and glycobiology has been limited
by technical challenges in glycan sequencing and glycan
synthesis, and insufficient tools to characterize the temporal
and spatial expression of glycan determinants at high resolution.
These barriers are coming down, providing enhanced
opportunities to decode glycosylation function in physiology
and pathology.
Determining the sequences of glycan structures remains a
highly specialized technique that requires multiple orthogonal
approaches, microgram amounts of material isolated from
proteins or lipids, and does not capture the spatial and temporal
nature of the glycan itself. Glycan synthesis also presents
significant challenges. Functional synthetic glycans must retain
the correct linkages between sugars in the correct stereochemical
orientation. Clay Bennett introduced ways in which the
stereochemical outcome of glycosylation can be controlled using
methods that are accessible to novice synthetic chemists and
scalable (Zhuo et al., 2019; Ling and Bennett, 2020).
Democratizing glycan synthesis can advance glycomedicine, as
evidenced by the development of synthetic glycans capable of
targeting drug resistant pathogens and a potentially new class
of antibiotic drugs.
To define the localization of glycans, identify their components,
and explore their functions in biological tissues, the most
commonly utilized tools in the glycobiologist’s toolkit are lectins
and monoclonal antibodies (mAbs). Lectins, which are GBPs
found in animals and plants, are used extensively, although
their broad specificity can limit their utility. For example, three
plant lectins are commonly used to distinguish between two
biologically important structures: α2-3 linked sialic acid (bound
by MAL, Maackia amurensis lectin I and II) and α2-6 linked
sialic acid (bound by SNA, Sambucus nigra agglutinin). However,
MAL-I and MAL-II also bind 3-O-sulfated determinants and
SNA binding can be inhibited by lactose or galactose. Thus,
interpretation of such experiments always requires caveats.
Addressing this challenge, Lori Yang presented exciting
technology in development to engineer more specific GBPs
called Lectenz®. These proteins are engineered from carbohydrateprocessing enzymes that exhibit high specificity and affinity
for monosaccharides and glycosidic linkages. By eliminating
catalytic activity and enhancing affinity using directed evolution
informed by computational predictions of known molecular
interactions, enhanced GBPs are generated. In theory, this
innovative approach could convert any glycoactive enzyme to
a binding reagent that is far more specific than traditional
Frontiers in Microbiology | www.frontiersin.org

DISCUSSION
The workshop presentations briefly reviewed above highlight
the importance of research in glycobiology for the advancement
of fundamental knowledge and human health. Approaches from
glycome profiling to glycan engineering have deepened our
understanding of glycan mediated host-pathogen interactions
and regulation of host immunity. This understanding in turn
increases our ability to develop feasible approaches for diagnosis,
treatment, and prevention of infectious disease as well as for
control of both protective and dysregulated immune responses.
Further development of tools and resources to help
characterize, localize, and engineer glycans and glycan-binding
proteins will accelerate discovery and application in both
infection and immunity. Studies of infection will benefit from
analysis and synthesis of microbial glycans, examination of
the host activities and glycoconjugates that modulate events
4
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at the host-pathogen interface, the use of microbe diversity
to uncover new processes and cellular interactions, and the
expansion and availability of glycan arrays that reflect the
diversity of microbes and their host niches. Studies of immunity
will benefit from the ability to analyze, create, and regulate
specifically glycosylated antibodies to control immune outcomes;
therapeutically regulate cell surface glycans to modulate their
responsiveness target intercellular glycosylation to modulate
signaling pathways; and target native immune inhibitory
pathways with glycans. Robust support of these efforts will
continue to yield exciting scientific discoveries and improved
human health.
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